403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
RNA Therapeutics Market Size To Hit USD 26.13 Billion By 2034
| Report Attribute | Details |
| Market size value in 2025 | USD 8.55 billion |
| Revenue forecast in 2034 | USD 26.13 billion |
| Growth rate | CAGR of 13.22% from 2025 to 2034 |
| Base year for estimation | 2024 |
| Historical data | 2021 - 2024 |
| Forecast period | 2025 - 2034 |
| Quantitative units | Revenue in USD million/billion and CAGR from 2025 to 2034 |
| Report coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments covered | By Type, By Product, By Indication, By End-User, By Region |
| Regional scope | North America; Europe; Asia Pacific; Latin America; MEA |
| Country scope | U.S.; Canada; Mexico; UK; Germany; France; Italy; Spain; Denmark; Sweden; Norway; India; China; Japan; Australia; South Korea; Thailand; Brazil; Argentina; Saudi Arabia; UAE; South Africa; Kuwait |
| Customization scope | Free report customization (equivalent up to 8 analyst's working days) with purchase. Addition or alteration to country, regional & segment scope. |
For more information, visit the Nova One Advisor website or email the team at ... | Call us: +1 804 420 9370
What are the Key trends in the RNA Therapeutics Market in 2024?
- In October 2024, European regulators suspended all clinical trials of Sarepta Therapeutics' gene therapy, Elevidys, after the death of a U.S. teenager who had received the treatment. Elevidys, developed for Duchenne muscular dystrophy, had previously been administered to more than 800 patients worldwide before the pause. In July 2024, GSK acquired CureVac's shares in their joint influenza and COVID-19 vaccine programs, making an upfront payment of €400 million with potential milestones totaling €1.05 billion. The acquisition is intended to enhance GSK's expertise and capacity in mRNA vaccine technology.
What is the Emerging Challenge in the RNA Therapeutics Market?
A major emerging challenge is the development of safe and efficient delivery systems to ensure targeted delivery of RNA molecules without triggering immune reactions. Additionally, high production costs, complex manufacturing processes, and stability issues of RNA compounds pose hurdles. Regulatory uncertainties and limited long-term safety data further complicate large-scale commercialization and patient accessibility.
Available for purchase directly at -RNA Therapeutics Market Segmental Insights
By Type Insights
What made the mRNA Therapeutics Segment Dominant in the RNA Therapeutics Market in 2024?
The mRNA therapeutics segment led the market due to its proven success in vaccine development, particularly during the COVID-19 pandemic. Its ability to enable rapid drug design, high efficacy, and targeted treatment has accelerated adoption across various therapeutic areas, including oncology and infectious diseases. Additionally, strong R&D investments, technological advancements, and growing regulatory support have further strengthened the dominance of mRNA-based therapeutics in the global market.
The RNA interference
By Product Insights
How did Vaccines Segment Dominate the RNA Therapeutics Market in 2024?
The vaccines segment captured the largest market share in 2024, owing to growing advancements in RNA technology and increasing investment in next-generation immunization programs. Rising demand for personalized and therapeutic vaccines targeting infectious and chronic diseases also fueled growth. Additionally, improved delivery platforms and strong regulatory backing for RNA-based vaccine innovations reinforced the segment's leading position in the global market.
The drug segment is expected to grow at the fastest CAGR during the forecast period due to increasing advancements in RNA-based drug development and expanding applications across cancer, rare genetic, and metabolic disorders. The ability of RNA therapeutics to precisely target disease pathways at the molecular level is driving innovation. Furthermore, rising investments in clinical trialsBy Indication Insights
Why the Infectious Diseases Segment Dominated the RNA Therapeutics Market in 2024?
The infectious diseases
The rare genetic disorders
By End User Insights
What Made the Hospitals & Clinics Segment Dominant in the RNA Therapeutics Market in 2024?
The hospitals & clinics segment dominated the market due to its crucial role in administering advanced RNA-based treatments and vaccines under professional supervision. These facilities provide the necessary infrastructure for safe drug delivery, patient monitoring, and adverse reaction management. The growing adoption of RNA therapies for both infectious and genetic diseases, along with increased hospital collaboration with biotech firms for clinical trials, further strengthened dominance in the market.
The research institutes segment is projected to grow at the fastest CAGR during the forecast period, driven by increasing investments in RNA-based drug discovery and innovation. These institutions play key role in advancing RNA sequencing, gene editing, and delivery technologies. Growing collaboration between academia and biotechnology
By Regional Analysis
How is North America contributing to the Expansion of the RNA Therapeutics Market?
North America dominated the market in 2024 due to strong biotechnology infrastructure, robust funding for RNA research, and the presence of key industry players like Moderna, Pfizer, and Alnylam Pharmaceuticals. The region's well-established regulatory framework and rapid adoption of advanced therapeutics further supported market growth. Additionally, the high prevalence of genetic and chronic diseases, combined with continuous clinical trials and government initiatives to promote RNA-based treatments, reinforced North America's leading market position.
- For Instance, As of January 2024, the U.S. had 21 FDA-approved RNA-based therapies and around 131 others in clinical development, with RNAi and mRNA accounting for nearly 77% of the pipeline. These treatments cover about 15 therapeutic areas, including rare disorders, and often allow for less frequent dosing. Although most candidates are in early stages, 29 are in late-stage trials, indicating strong prospects for future regulatory approvals.
How is Asia-Pacific Accelerating the RNA Therapeutics Market?
Asia-Pacific is anticipated to grow at the fastest CAGR in the market during the forecast period due to increasing investments in biotechnology research, expanding healthcare infrastructure, and growing collaborations with global pharmaceutical companies. Rising government support for precision medicine, coupled with a surge in genetic disorder cases and infectious diseases, is driving regional demand. Moreover, the rapid adoption of mRNA technologies and growing clinical research activities in countries like China, Japan, and India are accelerating market growth.
- For Instance, In August 2024, Bayer entered into a collaboration with NextRNA Therapeutics to develop innovative cancer therapies using long non-coding RNA (lncRNA) technology. The partnership, potentially worth up to $547 million, aims to leverage NextRNA's expertise in RNA-based drug discovery to advance Bayer's oncology pipeline and strengthen its position in precision cancer treatment.
RNA Therapeutics Market Top Key Companies:
- Moderna, Inc.
A global leader in mRNA technology, Moderna played a pivotal role in commercializing mRNA vaccines, particularly for COVID-19. The company continues to expand its RNA pipeline targeting infectious diseases, cancer, and rare conditions.
- Alnylam Pharmaceuticals
A pioneer in RNA interference (RNAi) therapeutics, Alnylam has multiple FDA-approved RNAi drugs (e.g., Onpattro, Givlaari). It focuses on rare genetic, cardio-metabolic, and hepatic diseases.
- Ionis Pharmaceuticals
The company specializes in antisense oligonucleotide (ASO) therapies and has a robust RNA drug pipeline. Ionis has partnered with companies like Biogen and AstraZeneca for broader therapeutic reach.
- BioNTech SE
Known for its co-development of the first approved mRNA COVID-19 vaccine with Pfizer, BioNTech is expanding its mRNA platform into oncology and other infectious diseases.
- CureVac N.V.
It focuses on developing mRNA-based vaccines and therapeutics, including treatments for COVID-19, influenza, and cancer. CureVac is also investing in next-gen mRNA technology for better stability and efficacy.
- Arrowhead Pharmaceuticals
It develops RNAi-based drugs primarily for liver-targeted diseases. Arrowhead has partnerships with major pharma players like Janssen and Takeda.
- Sirnaomics, Inc.
Sirnaomics specializes in RNAi therapeutics with a focus on oncology and fibrotic diseases. The company is advancing a proprietary delivery platform to enhance therapeutic efficiency.
- Silence Therapeutics
The company is a leader in RNAi therapeutics, targeting diseases with high unmet need, particularly in hematology and cardiovascular disorders. The company uses GalNAc-conjugation for targeted delivery to the liver.
- Translate Bio (Acquired by Sanofi)
It brought expertise in mRNA-based therapies for infectious and rare diseases. Now part of Sanofi's growing RNA therapeutics capabilities.
- Arcturus Therapeutics
It develops mRNA vaccines and therapeutics using its proprietary LUNAR® delivery platform. Arcturus is also advancing self-amplifying mRNA (saRNA) technology to lower dosing needs.
More Insights in Nova One Advisor:
- U.S. mRNA Therapeutics Market - The U.S mRNA Therapeutics market size mRNA Therapeutics Contract Development & Manufacturing Organization Market - The mRNA therapeutics contract development & manufacturing organization market size mRNA Therapeutics Market - The global mRNA therapeutics market size Natural Killer Cells Therapeutics Market - The global natural killer cells therapeutics market size Lymphoma Therapeutics Market - The global lymphoma therapeutics market size Non-small Cell Lung Cancer Therapeutics Market - The global non-small cell lung cancer therapeutics market size U.S. Drug Discovery Outsourcing Market - The U.S. drug discovery outsourcing market size Leukemia Therapeutics Market - The global leukemia therapeutics market size Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market - The global castration-resistant prostate cancer (CRPC)/HRPCA therapeutics market size Anti-Inflammatory Therapeutics Market - The global anti-inflammatory therapeutics market size Cystic Fibrosis Therapeutics Market - The global cystic fibrosis therapeutics market size Protein Therapeutics Market - The global protein therapeutics market size Digital Therapeutics Market - The global digital therapeutics market size U.S. Digital Therapeutics Market - The U.S. digital therapeutics market Pet Cancer Therapeutics Market - The pet cancer therapeutics market size Plasma Protein Therapeutics Market - The plasma protein therapeutics market size Asthma Therapeutics Market - The global asthma therapeutics market size
RNA Therapeutics Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2019 to 2034. For this study, Nova One Advisor has segmented the global RNA therapeutics market
By Type
- RNA Interference (RNAi) Therapeutics mRNA Therapeutics Antisense Oligonucleotide (ASO) Therapeutics Others
By Product
- Vaccines Drugs
By Indication
- Rare Genetic Disorders/Hereditary Diseases Infectious Diseases Others (Metabolic Disorders, Auto-immune Disorders, and Oncology)
By End-User
- Research Institutes Hospitals & Clinics
By Regional
- North America Europe Asia Pacific Latin America Middle East & Africa
About-Us
Nova One Advisor is a global leader in market intelligence and strategic consulting, committed to delivering deep, data-driven insights that power innovation and transformation across industries. With a sharp focus on the evolving landscape of life sciences, we specialize in navigating the complexities of cell and gene therapy, drug development, and the oncology market, enabling our clients to lead in some of the most revolutionary and high-impact areas of healthcare.
Our expertise spans the entire biotech and pharmaceutical value chain, empowering startups, global enterprises, investors, and research institutions that are pioneering the next generation of therapies in regenerative medicine, oncology, and precision medicine.
Our Trusted Data Partners
Towards Chemical and Materials | Precedence Research | Statifacts | Towards Packaging | Towards Healthcare | Towards Food and Beverages | Towards Automotive | Towards Consumer Goods | Nova One Advisor | Nutraceuticals Func Foods | Onco Quant | Sustainability Quant | Specialty Chemicals Analytics | Towards Chem and Material Web:Contact Us
USA: +1 804 420 9370
Email: ... For Latest Update Follow Us: LinkedIn
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
More Story
Comments
No comment